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Epigenetic evidence for involvement 
of the oxytocin receptor gene in obsessive–
compulsive disorder
Carolina Cappi1*†, Juliana Belo Diniz1†, Guaraci L. Requena2, Tiaya Lourenço1, Bianca Cristina Garcia Lisboa1, 
Marcelo Camargo Batistuzzo1, Andrea H. Marques1, Marcelo Q. Hoexter1, Carlos A. Pereira2, 
Euripedes Constantino Miguel1 and Helena Brentani1
Abstract 
Background: Obsessive–compulsive disorder (OCD) is a chronic neurodevelopmental disorder that affects up to 3% 
of the general population. Although epigenetic mechanisms play a role in neurodevelopment disorders, epigenetic 
pathways associated with OCD have rarely been investigated. Oxytocin is a neuropeptide involved in neurobehavio-
ral functions. Oxytocin has been shown to be associated with the regulation of complex socio-cognitive processes 
such as attachment, social exploration, and social recognition, as well as anxiety and other stress-related behaviors. 
Oxytocin has also been linked to the pathophysiology of OCD, albeit inconsistently. The aim of this study was to 
investigate methylation in two targets sequences located in the exon III of the oxytocin receptor gene (OXTR), in OCD 
patients and healthy controls. We used bisulfite sequencing to quantify DNA methylation in peripheral blood samples 
collected from 42 OCD patients and 31 healthy controls.
Results: We found that the level of methylation of the cytosine-phosphate-guanine sites in two targets sequences 
analyzed was greater in the OCD patients than in the controls. The higher methylation in the OCD patients correlated 
with OCD severity. We measured DNA methylation in the peripheral blood, which prevented us from drawing any 
conclusions about processes in the central nervous system.
Conclusion: To our knowledge, this is the first study investigating DNA methylation of the OXTR in OCD. Further 
studies are needed to evaluate the roles that DNA methylation and oxytocin play in OCD.
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Background
Obsessive–compulsive disorder (OCD) [1] is a chronic 
psychiatric illness with a lifetime prevalence of 1–3% in 
the general population [2]. The results of twin and fam-
ily studies indicate that inherited factors along with non-
shared family environmental factors may be etiologically 
related to OCD [3]. However, genome wide association 
studies have failed to find risk alleles of major effect for 
OCD [4]. Therefore, investigators have expanded the 
model of susceptibility to include contributions of rare 
de novo as well as genetic and epigenetic inherited vari-
ations [5].
The neuropeptide oxytocin has been linked to emo-
tional regulation processes in recent years. Its therapeu-
tic use has gained momentum, and several trials have 
investigated the effects of oxytocin administration for the 
emotional responses of psychiatric disorder patients [6]. 
Oxytocin anxiolytic properties and its effects over proso-
cial behaviors have been raised as putative therapeutic 
characteristics of this molecule. So far, the socializing 
effects of oxytocin have been shown to be potentially 
promising for the treatment of autism disorder. In 
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addition, one trial with 15 autistic patients has found that 
the continuous intravenous administration of oxytocin 
led to reduction of repetitive behaviors [7].
Paradoxically, while oxytocin is linked to anxiolytic 
effects and to improvement of repetitive behaviors 
in autism, elevated oxytocin levels are also putatively 
involved in the etiology of OCD repetitive behaviors. 
Clinical trials that investigated the therapeutic use of 
oxytocin in OCD found no effect of this molecule over 
the frequency of repetitive symptoms (neither improve-
ment nor worsening) [8, 9]. In contrast, Leckman et  al. 
[10] reported that levels of oxytocin in ventricular cer-
ebrospinal fluid (CSF) are higher in OCD patients than 
in healthy controls and identified a positive correlation 
between higher CSF levels of oxytocin and higher fre-
quency of repetitive behaviors. However, in a subsequent 
study, Altemus et al. [11]. were unable to replicate those 
findings.
The aforementioned inconsistences in findings relat-
ing oxytocin to OCD repetitive behaviors highlight the 
potential complexity of such association. The absence of 
effects of the acute administration of oxytocin in neither 
improvement nor worsening of OCD symptoms suggest 
that current variation of this neuropeptide may not be 
relevant for the better understanding of OCD etiology 
[8, 9]. However, despite the lack of significance of cur-
rent oxytocin levels, pre-natal and early-natal exposure 
to high levels of oxytocin could still be potentially related 
to the future outbreak of OCD repetitive behaviors. Cor-
roborating this hypothesis, oxyctocin has been previously 
shown to moderate the effects of early social experiences 
in later life [12].
Epigenetics is the study of the biological mechanisms 
that explain how environmental influences result in 
dynamic variations in physiology and adaptive behaviors 
without changes in the DNA sequence. There are devel-
opmental windows of epigenetic reprogramming such 
that exposures occurring during these dynamic periods 
are more likely to produce changes to the epigenome 
[13]. Therefore, the investigation of epigenetic markers 
might be a tool to understand the effect of events that 
occurred at critical periods of the development and later 
along the life spam.
The most widely studied epigenetic alteration in 
humans is DNA methylation (DNAm), which is one 
of the main epigenetic mechanisms that control gene 
expression [14]. In mammalian cells, most DNA methyla-
tion occurs on cytosines that precede a guanine nucleo-
tide at loci known as cytosine-phosphate-guanine (CpG) 
sites [14]. Methylation of oxytocin receptor gene (OXTR) 
has been associated with autism [15], psychopathy [16], 
acute psychosocial stress in the population experienced 
war adversities early in life [17] and anorexia [18].
The objective of this study was to assess DNA meth-
ylation in the OXTR gene in patients with OCD and in 
healthy controls. We observed two targets sequences 
located in the exon III of OXTR gene, which are part of 
the CpG island comprising exons I–III [17]. We hypoth-
esized that the OCD patients would show alterations in 
OXTR methylation possibly related to epigenetic repro-
gramming in critical periods of development.
Methods
In this study, we evaluated 43 OCD outpatients and 34 
healthy controls (i.e., individuals with no history of an 
Axis I mental disorder). We recruited subjects from the 
general population through media advertisements, and 
we conducted all evaluations at the University of São 
Paulo School of Medicine Institute of Psychiatry, in the 
city of São Paulo, Brazil, between 2006 and 2008. Patients 
and healthy subjects also participated in other clinical tri-
als conducted by our group [19, 20]. We applied the fol-
lowing inclusion criteria: being between 18 and 65 years 
of age; having received a primary DSM-IV diagnosis of 
OCD; and having a Yale-Brown Obsessive–Compul-
sive Scale (Y-BOCS) [21] score of ≥16 for obsessions 
and compulsions or ≥10 for obsessions or compulsions 
alone. We excluded individuals who had previous history 
of substance abuse or dependence, psychosis, or head 
injury with loss of consciousness, as well as those at risk 
for suicide, or with any medical disorder that could affect 
the central nervous system, and those who were pregnant. 
Controls were selected among hospital and university 
staff. They were selected according to the same criteria 
described to the patients (except for the presence of OCD) 
and had no current history of neurological or psychiatric 
disorders on the basis of SCID interviews. All partici-
pants provided written informed consent, which had been 
approved by the local Institutional Review Board.
In our clinical assessment of the participants, we 
applied the semi-structured and structured interviews 
employed in the Brazilian Research Consortium on 
Obsessive–Compulsive Spectrum Disorders project 
[22]: the Structured Clinical Interview for DSM-IV Axis 
I Disorders; those with any Axis I psychiatric diagnosis, 
and also symptomatology scales as the Beck Depression 
Inventory (BDI) [23]; the Yale Global Tic Severity Scale 
[24]; and the Beck Anxiety Inventory (BAI) [25]. We 
quantified level of education as years of schooling minus 
the number of grades repeated.
Of the 43 OCD patients evaluated, 33 were treatment-
naïve, six had received fluoxetine for 2 weeks, and three 
had received cognitive-behavior therapy for 2 weeks [26]. 
Treatment was part of other research protocols taking 
place at the same institution. Such protocols were not 
related to this study’s methodology.
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Genomic DNA extraction
We obtained DNA from peripheral blood leucocytes. 
The blood was drawn before treatment initiation or up 
to two weeks of undergoing treatment. We subsequently 
extracted genomic DNA using the “salting-out” method 
[27, 28].
DNA methylation analysis
We treated genomic DNA (1000  ng) with sodium 
bisulfite, using the EpiTect Bisulfite Kit (QIAGEN) in 
accordance with the manufacturer’s standard proto-
col. We performed bisulfite-specific polymerase chain 
reaction (PCR) amplification of two target sequences 
is located in the exon III of OXTR gene (OXTR1—cat. 
PM00016821 and OXTR2—cat. PM00016828, QIAGEN), 
using the PyroMark PCR Kit (QIAGEN). Both target 
sequences are in the CpG island comprising exons I–III 
[17]. This CpG island had been already associated with 
the regulation of OXTR gene expression in specific tissue 
[29].
The OXTR1 target sequence has 34 pb with 4 CpG sites 
analyzed (AGGCGGCACAGCAGGTCGGGCCCGTAG 
AAGCGGA) and the OXTR2 target sequence has 34 bp 
with 5 CpG sites analyzed (CCGTAGCAGGYAGCGAGC 
ACGATGACCGGCACGA) (Fig. 1).
Using the PyroMark PCR Kit, we generated amplicons 
in a reaction volume of 25 µl containing 250 nM each of 
the forward and reverse PCR primers, together with 1 µl 
(≈50  ng) of bisulfite-treated DNA. We performed the 
PCR with the following conditions for all reactions: 95 °C 
for 15 min; 42 cycles at 95 °C for 30 s, 56 °C for 30 s, and 
72 °C for 30 s; 1 cycle at 72 °C for 5 min; and a final exten-
sion at 4  °C. We prepared single-stranded biotinylated 
PCR products for sequencing using the Pyrosequencing 
Vacuum Prep Tool (QIAGEN) in accordance with the 
manufacturer’s instructions. For each assay, we added 
0.3  µM of the sequencing primer in 25  µl of annealing 
buffer per well. Pyrosequencing is a quantitative sequenc-
ing method that allows cytosine methylation to be quan-
tified (in %) at each CpG site within a given sequence. We 
also applied DNA methylation quality controls, blinding 
evaluators to the diagnosis and randomly distributing 
the samples on plates, thus avoiding experimental biases, 
as well as assessing the quality of the pyrosequencing 
(including peak height, deviation from the reference 
sequence pattern, and unexpected peak height).
Previous studies have shown that the Pyrosequencing 
method is adequate for the evaluation of methylation 
patterns that are gene-specific [30]. In addition, in com-
parison with other methodologies, Pyrosequencing has 
been shown to yield similar results for methylation pat-
terns [31].
We analyzed the data using PyroMark Q24 allele 
quantification software, version 2.0.6 (QIAGEN), which 
allowed us to calculate the proportional methylation. 
Each site received a quality score of “passed”, “check”, or 
“failed”. The minimum signal value for a peak to achieve 
a quality score of “passed” in the base-called sequence 
was 10. The minimum signal value for a peak to achieve 
a quality score of “check” in the base-called sequence was 
5. We assigned a quality score of “failed” to peaks with a 
signal value lower than 5. We excluded “failed” samples 
from the analysis, and we reanalyzed samples with peak 
signal values between 5 and 9. All of the blank controls 
used in the quality control process tested negative.
Statistical analysis
To compare the OCD patients and the healthy controls, 
in terms of the common symptomatology (BDI and BAI 
scores) and demographic data, we used nonparametric 
method for comparing medians between populations, 
named Quor, as proposed by [32]. This method calculate 
Fig. 1 Representation of the two sequence targets in the exon III of the OXTR gene. Legend: Representation of OXTR gene with the CpG island in 
green and the location of exon III in blue. The dashed lines show the amplification of the region analyzed that contains two targets, OXTR1 OXTR2. 
The target sequences are in the exon III of OXTR gene (OXTR1—cat. PM00016821 and OXTR2—cat. PM00016828, QIAGEN), using the PyroMark PCR 
Kit (QIAGEN). Both regions are in the CpG island the comprise exons I–III. The OXTR1 target sequence has 34 pb with 4 CpG sites analyzed and the 
OXTR2 target sequence has 34 bp with 5 CpG sites analyzed
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the confidence statement that the median of patients 
population is less than the median of controls population 
or (vice versa) [32, 33]. We tested the normal distribution 
of data related to the OXTR CpG sites, using the Shap-
iro–Wilk test. The data of CpG sites related to the OXTR1 
and OXTR2 target sequence did not present normal dis-
tribution for patients and controls. Therefore, in subse-
quent analyses, we employed tests that do not assume 
normal distribution. To identify differences in methyla-
tion sites between patients and controls, we used Hotel-
ling’s T2 test with Chi-square approximation, [34] which 
is a multivariate test, analog of the univariate two-sample 
t test, to compare the means of two multivariate popu-
lation. We conducted post hoc analyses using the Quor 
method [35]. After the post hoc analysis, we used Ken-
dall’s tau rank correlation coefficient test to determine 
whether the OXTR CpG sites in both target sequences 
were associated with clinical and demographic variables 
(age, sex, level of education, BDI score, BAI score, tics, 
and Y-BOCS score). Kendall’s tau rank correlation coef-
ficient test is a nonparametric rank correlation test for 
hypothesis testing in small samples for which the data 
present non-normal distributions [36].
We performed a linear regression analysis for the log of 
the mean of methylation levels considering both targets 
sequences for CpG OXTR gene, including clinical and 
demographic variables (age, sex, level of education, BDI 
score, BAI score, tics, and Y-BOCS score). The level of 
significance was set at p ≤ 0.05. All statistical tests were 
two-tailed, and we performed all statistical analyses using 
the software R, version 2.14.1 (R Development Core 
Team).
Results
After the pyrosequencing analysis, one patient and three 
controls were excluded by lower quality of score to ana-
lyze the methylation. Therefore, the final sample com-
prised 42 OCD patients and 31 healthy controls. Table 1 
shows the clinical and demographic characteristics of 
the participants. The median age, sex, and level of edu-
cation was similar between the two groups. The OCD 
patients scored higher on the BDI and BAI, indicating 
that the population median for the healthy controls was 
lower than was that of the OCD patients, with a high 
confidence.
Methylation patterns
The dispersion graph displayed in Fig. 2 shows the pro-
portional methylation in the two target sequences located 
in the exon III of OXTR gene in OCD patients and healthy 
controls. The two target sequences evaluated (one with 5 
and other with 4 CpG sites) had levels of methylation that 
differed significantly between OCD patients and healthy 
controls (OXTR1—T2  =  59.2; p  <  0.001; and OXTR2—
T2 = 26.6; p < 0.001). We also performed the Hotelling’s 
T2 test with the Chi square approximation between the 
controls and patients who received medication or CBT 
and drug naïve. The level of methylation did not differ 
between the drug-naïve patients (n = 33) and the patients 
who had already started any treatment (n = 9). Although 
is important to note that the sample size is rather low to 
support an analysis of sub-group effects.
Post-hoc analysis showed high confidence (>0.9) for a 
statement that the population median for all CpG sites 
of the OXTR 1 and OXTR 2 target sequences were lower 
in the healthy control group than in the OCD patients 
group (Table 2).
To determine whether any of the nine CpG sites cor-
related with specific clinical features that might be 
related with methylation, we observed if BDI score, 
BAI score, positive diagnosis of tic disorder, and the 
severity of OCD symptoms, as well as with age, sex, 
and level of education, in the OCD patients were 
correlate with any result of methylation in CpG sites 
(Table  3). In some of the OXTR1 CpG sites (CpG 
units 1, 3, and 4) and in all of the OXTR2 CpG sites, 
Table 1 Demographic and clinical characteristics of patients with obsessive–compulsive disorder and healthy controls
Except for sex, values are presented as mean/median (SD)
OCD obsessive–compulsive disorder, BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, MpC population median for the control group, MpP population 
median for the (OCD) patient group
a We used confidences (determined via the Quor method) in order to compare the population medians between the patient and control groups
Characteristic OCD patients Healthy controls p Confidencea
(n = 42) (n = 31) MpC < MpP MpP < MpC
Age 29.38/29 (8.65) 28.55/28 (9.28) – 0.28 0.28
Sex (male) 61% 64% 0.98 – –
Years of schooling 13.67/13 (3.07) 15.71/15 (4.4) – 0.01 0.58
BDI 18.69/20 (8.86) 2.13/1 (2.38) – 1.00 0.00
BAI 18.33/18 (11.1) 1.71/1 (1.81) – 1.00 0.00
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the individual methylation level correlated negatively 
with the BDI score (Table  3). Although three of the 
OCD patients had been diagnosed with a tic disorder, 
we found no correlation between tics and the level of 
methylation.
After that we performed a linear regression analy-
sis, using log of the mean of methylation levels consid-
ering both targets sequences for CpG OXTR gene and 
the clinical and demographic variables as a predictor of 
level of methylation (age, sex, level of education, BDI 
score, BAI score, tics, and Y-BOCS score). We found 
that the Y-BOCS score was the main determinant of the 
methylation level (β = 0.02; p < 0.001) and also the BDI 
score (β = − 0.013; p = 0.0037) (Table 4).
Discussion
To our knowledge, this is the first study investigating 
OXTR DNA methylation in OCD. Our analysis revealed 
hypermethylation in the CpG sites of two sequences 
targets located in the exon III, which are part of the 
CpG island that comprise exons I–III of OXTR gene, in 
patients with OCD when compared to healthy subjects 
and a positive correlation between hypermethylation and 
OCD symptom severity. A number of studies have shown 
that this CpG island that comprise exons I–III, is associ-
ated with transcription of the OXTR gene [17, 29, 37, 38]. 
Therefore, the high levels of DNA methylation observed 
in both of the OXTR sequences targeted in our study 
could be related with the transcription of the OXTR gene.
In a previous study, Gregory et al. investigated the CpG 
island that overlaps exons I–III of OXTR gene in a cohort 
of autistic patients and healthy subjects. When com-
pared to healthy subjects, autistic patients had hyper-
methylated OXTR in two different types of tissue: the 
peripheral blood mononuclear cells and in the temporal 
cortex. The similarities in epigenetic profiles from these 
two tissue types of ectodermal (peripheral blood) and 
mesodermal (temporal cortex) origin are possible since 
epigenetic profiles undergo reprogramming during very 
early gestation [15]. Therefore, our finding might indicate 
that, at some critical point of development, environmen-
tal factors led to hypermethylation of the OXTR in OCD 
patients but not in healthy subjects.
In rats, grooming behaviors are a putative model for 
OCD, and the injection of oxytocin into the amygdala 
has been shown to induce grooming behaviors in those 
Fig. 2 Dispersion graph of the % of methylation in OXTR1 and OXTR2. Legend: Red and blue dots represent the % of methylation in the two target 
sequences in the exon III of OXTR gene in OCD individuals and controls, respectively. The black dot represents the median
Table 2 Median methylation levels of  cytosine-phos-
phate-guanine units in  patients with  obsessive–compul-
sive disorder and healthy controls
OCD obsessive–compulsive disorder, CpG cytosine-phosphate-guanine; 
OXTR oxytocin receptor, MpC population median for the control group, 
MpP population median for the (OCD) patient group
OXTR  
gene
CpG  
island unit
OCD 
patients
Healthy 
controls
Confidence
(n = 42) (n = 31)
Median Median MpC < MpP
OXTR1 1 8.19 5.71 0.9608
OXTR1 2 5.24 2.32 0.9995
OXTR1 3 2.53 1.55 0.9983
OXTR1 4 9.62 7.97 0.9436
OXTR2 1 11.65 8.62 0.9275
OXTR2 2 25.46 18.01 0.9591
OXTR2 3 27.86 19.09 0.9846
OXTR2 4 15.50 11.50 0.9559
OXTR2 5 18.99 12.65 0.9625
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animals [39]. Since oxytocin increases grooming and, 
in other circumstances, reduces fear, it is tempting to 
hypothesize that oxytocin-induced grooming behaviors 
are anxiolytic. In OCD, compulsions are performed to 
alleviate anxiety corroborating the idea of the anxiolytic 
effect of grooming [40]. Therefore, OXTR hypermethyla-
tion could be a marker of higher oxytocin levels during 
a critical period of development when “grooming-like 
behaviors” are established as “preferential counter-anxi-
ety behaviors”. It is important to highlight, however, that 
this hypothesis remains highly speculative at this point.
In the present study, we also found a negative corre-
lation between the level of methylation and the sever-
ity of depressive symptoms. Previously, higher CSF 
levels of oxytocin had been associated with higher 
severity of depressive symptoms in children and 
adolescents with OCD [41]. As well, a positive corre-
lation between baseline plasma and salivary oxytocin 
levels and depressive symptoms has been described in 
healthy subjects [42].
However, in patients with major depression, lower con-
centrations of cerebrospinal fluid and plasmatic levels 
of oxytocin have been associated with lower severity of 
depressive symptoms [43]. Such inconsistences suggest 
that, similarly to what occurs with OCD, the relation-
ship of oxytocin and depressive symptoms might not 
be related to current oxytocin levels. More likely, previ-
ous exposure to environmental factors that led to OXTR 
hypermethylation might impact the likelihood of later 
emergence of depressive symptoms.
The interpretation of our results should to be regarded 
with caution due to the gaps in our current knowledge 
about the mechanisms of epigenetic control along the life 
cycle. Although environmental influences and stochastic 
events can cause changes in the pattern of DNA meth-
ylation, these epigenetic markers are mostly susceptible 
to change during epigenetic reprogramming that occurs 
preferentially but not exclusively in early development 
[44–46]. In addition, epigenetic markers are tissue-spe-
cific and site-specific. Therefore, the methylation pattern 
found in a specific population of one cell type does not 
necessarily reflect the methylation pattern of other cell 
types, such as neurons. In our study, we did not confirm 
Table 3 Kendall’s correlation analysis of  methylation status of  the oxytocin receptor gene in  relation to  demographic 
and clinical variables in patients with obsessive–compulsive disorder (n = 42)
OXTR oxytocin receptor, CpG cytosine-phosphate-guanine, BDI Beck Depression Scale Inventory, BAI Beck Anxiety Scale Inventory, Y-BOCS Yale-Brown Obsessive–
Compulsive Scale, τ Kendall’s tau rank correlation coefficient
Values are presented as τ (p)
OXTR  
gene
CpG  
island unit
Age Sex Level of  
education
BDI BAI Tics Y-BOCS
OXTR1 1 τ = 0.046 
(0.679)
τ = 0.001 
(0.999)
τ = −0.089 
(0.434)
τ = −0.272 
(0.013)
τ = −0.115 
(0.296)
τ = −0.082 
(0.534)
τ = 0.013 (0.913)
OXTR1 2 τ = 0.034 
(0.760)
τ = 0.157 
(0.227)
τ = −0.029 
(0.799)
τ = −0.141 
(0.199)
τ = −0.055 
(0.617)
τ = 0.082 
(0.534)
τ = 0.058 (0.601)
OXTR1 3 τ = 0.086 
(0.434)
τ = 0.168 
(0.198)
τ = 0.059 
(0.604)
τ = −0.322 
(0.003)
τ = −0.122 
(0.267)
τ = 0.087 
(0.509)
τ = −0.118 
(0.286)
OXTR1 4 τ = 0.150 
(0.171)
τ = 0.011 
(0.937)
τ = −0.009 
(0.938)
τ = −0.336 
(0.002)
τ = −0.167 
(0.128)
τ = −0.077 
(0.560)
τ = −0.029 
(0.793)
OXTR2 1 τ = −0.023 
(0.839)
τ = −0.119 
(0.371)
τ = −0.074 
(0.522)
τ = −0.284 
(0.010)
τ = −0.165 
(0.137)
τ = −0.156 
(0.239)
τ = −0.033 
(0.769)
OXTR2 2 τ = −0.023 
(0.839)
τ = −0.129 
(0.329)
τ = −0.053 
(0.647)
τ = −0.244 
(0.028)
τ = −0.153 
(0.169)
τ = −0.135 
(0.309)
τ = −0.041 
(0.718)
OXTR2 3 τ = 0.026 
(0.821)
τ = −0.039 
(0.772)
τ = −0.069 
(0.552)
τ = −0.264 
(0.017)
τ = −0.138 
(0.215)
τ = −0.098 
(0.461)
τ = −0.043 
(0.701)
OXTR2 4 τ = −0.021 
(0.857)
τ = −0.068 
(0.611)
τ = −0.050 
(0.663)
τ = −0.234 
(0.035)
τ = −0.130 
(0.241)
τ = −0.104 
(0.437)
τ = −0.046 
(0.684)
OXTR2 5 τ = −0.021 
(0.857)
τ = −0.071 
(0.591)
τ = −0.066 
(0.567)
τ = −0.259 
(0.019)
τ = −0.135 
(0.223)
τ = −0.072 
(0.590)
τ = −0.048 
(0.668)
Table 4 Regression model for the log of the mean of meth-
ylation levels of  the oxytocin receptor 1 gene in  patients 
with obsessive–compulsive disorder
BDI Beck Depression Scale Inventory, Y-BOCS Yale-Brown Obsessive–Compulsive 
Scale
Parameter Estimate SE 95% CI p
Intercept 2.34 0.057 2.22–2.45 <0.001
BDI −0.013 0.006 −0.025 to −0.0014 0.029
Y-BOCS 0.02 0.005 0.01–0.03 <0.001
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if peripheral patterns of methylation reflected the pat-
terns of other tissue types. Therefore, we cannot deter-
mine in which tissue types the hypermethylation of the 
OXTR was established in our sample. We also do not have 
information about the current oxytocin levels in blood 
of OCD patients and controls and could not evaluate if 
hypermethylation of OXTR had any impact on peripheral 
availability of the neuropeptide oxytocin.
Conclusion
Our findings suggest that, at some critical point of devel-
opment, environmental factors led to hypermethylation 
of the OXTR in OCD patients but not in healthy subjects. 
Future studies should emphasize the gene-environmental 
relationships that might explain the hypermethylation of 
the OXTR in the pre-natal period and later emergence of 
OCD.
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